CVSA enters its Q3 FY2026 earnings call on May 1 carrying two unusually clear and opposing signals: a lead independent director who put nearly $3.8 million of his own money into the stock over six weeks, and a short position that just posted its biggest weekly build in months.
The insider signal is the harder one to ignore. Lead Independent Director Michael Malafronte made three separate purchases between March 3 and March 11, accumulating roughly 37,000 shares at prices around $98–$101 and committing approximately $3.75 million in net buying over the 90-day window. That's not a token allocation. It came at a point when the stock was trading well below current levels, and the size — clustered across multiple days — reads as deliberate conviction rather than a routine 10b5-1 plan fill. Against that backdrop, a small routine sell by a divisional president in mid-April adds little noise to the picture.
Short interest, meanwhile, moved sharply in the other direction this week. SI climbed 17.5% over the past seven days to 5.26% of free float — the highest reading since mid-to-late March. That reverses a month-long decline that had dragged short positioning from nearly 6% of float in mid-March all the way down to a low near 3.6% on April 8–9. The rebuild over the past fortnight has been methodical and consistent, day by day, with the pace accelerating into the final sessions of the week. Borrow is not the bottleneck: cost to borrow remains negligible at 0.43% APR, and availability in the lending pool is extremely loose, meaning new short positions face little friction to establish. The borrow market is not signalling a squeeze; it is signalling plentiful capacity for bears to press.
Options positioning offers a mild corroborating read on caution. The put/call ratio has nudged above its 20-day average — currently at 0.43 versus a mean of 0.41 — with a z-score just above 1. That's mildly more defensive than recent norms, but nowhere near the 1.5+ readings the name has seen at its most hedged over the past year. Options traders are not panicking into puts; they are just leaning a touch more defensively than the recent baseline.
The Street is thin but broadly constructive. Three buy-equivalent ratings are on record, with Barrington Research holding an Outperform at a $170 target and Truist Securities initiating at Buy with a $130 target in late March. At $114.62, those targets imply 14–48% upside from current levels. Valuation is not demanding: the EV/EBITDA multiple runs at approximately 8.5x, in line with where the sector has historically traded, and the P/E of roughly 13.8x has been drifting modestly lower over the past month. The bull case rests on enrollment momentum at Walden and Chamberlain — double-digit application growth and expanding EBITDA margins through operating leverage. The bear case points to Chamberlain enrollment weakness earlier attributed to marketing missteps, and the risk that forward multiples compress further if that softness persists. Covista's own medical schools released a headline this week noting a 97% combined first-time residency attainment rate, a data point the company will likely lean on in its prepared remarks on Thursday.
Peers have all drifted lower this week. PRDO fell nearly 5% on the week, LRN dropped 6.7%, and STRA was off 5.6%. CVSA held up better, down roughly 2.6% — suggesting the stock has either benefited from the insider buying narrative or simply seen less aggressive selling pressure into the print.
The earnings history adds context worth holding. The February 2026 print delivered a mild 2.5% one-day decline but fully recovered over the following five sessions. The January 2026 event was materially worse — down 6.5% on the day and off 12.8% over the week that followed. With shorts rebuilding methodically ahead of the May 1 call, the question going into Thursday is whether the enrollment story at Chamberlain has genuinely turned, and whether the AI-powered classroom partnership with Google Cloud announced on April 14 translates into any forward guidance that justifies the $170 bull target.
See the live data behind this article on ORTEX.
Open CVSA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
